Evidence map›Paper›PMID 31895772›Full record

ArticleMedicine2020

Identification of potential key genes for HER-2 positive breast cancer based on bioinformatics analysis.

Yuxiang Lin, Fangmeng Fu, Jinxing Lv, Mengchi Wang, Yan Li, Jie Zhang, Chuan Wang

Open access · goldAbstract read
In one paragraph

Article in Medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
1.8field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 34 citations in OpenAlex.

  1. TheInternational journal of molecular sciences · 2021
    Trial
  2. A RAC1 SUMOylation switch governs breast cancer metastasis.Signal transduction and targeted therapy · 2026
    Article
  3. Review
  4. Article
  5. Article
  6. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  7. Article
  8. Assessing the mechanism of fast-cycling cancer-associated mutations of Rac1 small Rho GTPase.Protein science : a publication of the Protein Society · 2024
    Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Yuxiang LinDepartment of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China.
Fangmeng FuDepartment of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China.
Jinxing LvDepartment of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China.
Mengchi WangBioinformatics and Systems Biology Graduate Program, University of California, San Diego, La Jolla, CA.
Yan LiDepartment of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China.
Jie ZhangDepartment of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China.
Chuan WangDepartment of Breast Surgery, Fujian Medical University Union Hospital, Fuzhou, Fujian Province, China.
Fujian Medical University · CNUnion Hospital · CNUniversity of California, San Diego · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundsHER-2 positive breast cancer is a subtype of breast cancer with poor clinical outcome. The aim of this study was to identify differentially expressed genes (DEGs) for HER-2 positive breast cancer and elucidate the potential interactions among them. MATERIAL AND

methodsThree gene expression profiles (GSE29431, GSE45827, and GSE65194) were derived from the Gene Expression Omnibus (GEO) database. GEO2R tool was applied to obtain DEGs between HER-2 positive breast cancer and normal breast tissues. Gene ontology (GO) annotation analysis and Kyoto Encyclopedia of Genes and Genome (KEGG) pathway enrichment analysis was performed by the Database for Annotation, Visualization and Integrated Discovery (David) online tool. Protein-protein interaction (PPI) network, hub gene identification and module analysis was conducted by Cytoscape software. Online Kaplan-Meier plotter survival analysis tool was also used to investigate the prognostic values of hub genes in HER-2 positive breast cancer patients.

resultsA total of 54 upregulated DEGs and 269 downregulated DEGs were identified. Among them, 10 hub genes including CCNB1, RAC1, TOP2A, KIF20A, RRM2, ASPM, NUSAP1, BIRC5, BUB1B, and CEP55 demonstrated by connectivity degree in the PPI network were screened out. In Kaplan-Meier plotter survival analysis, the overexpression of RAC1 and RRM2 were shown to be associated with an unfavorable prognosis in HER-2 positive breast cancer patients.

conclusionsThis present study identified a number of potential target genes and pathways which might impact the oncogenesis and progression of HER-2 positive breast cancer. These findings could provide new insights into the detection of novel diagnostic and therapeutic biomarkers for this disease.

Indexed as

Breast NeoplasmsCase-Control StudiesComputational BiologyDown-RegulationErb-b2 Receptor Tyrosine KinasesFemaleGene Expression Regulation, NeoplasticHumansrac1 GTP-Binding ProteinRibonucleoside Diphosphate ReductaseTranscriptomeUp-RegulationERBB2 protein, humanErb-b2 Receptor Tyrosine Kinasesrac1 GTP-Binding ProteinRAC1 protein, humanRibonucleoside Diphosphate Reductaseribonucleotide reductase M2

Identifiers

PMID31895772
PMCPMC6946304
OpenAlexW2998442977

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.